Test ID: GENTA Gentamicin, Trough, Serum
Useful For
Monitoring adequacy of drug clearance during gentamicin therapy
Method Name
Turbidimetric Immunoassay
Reporting Name
Gentamicin, Trough, SSpecimen Type
SerumSpecimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions:
1. Serum gel tubes should be centrifuged within 2 hours of collection.
2. Red-top tubes should be centrifuged, and the serum aliquoted into a plastic vial within 2 hours of collection.
Specimen Minimum Volume
0.25 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 7 days | |
Frozen | 14 days | ||
Ambient | 72 hours |
Clinical Information
Gentamicin is an antibiotic used to treat life-threatening blood infections caused by gram-negative bacilli, particularly Citrobacter freundii, Acinetobacter species, Enterobacter species, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii, Pseudomonas aeruginosa, and Serratia species. It is often used in combination with beta-lactam therapy.
A gentamicin minimal inhibitory concentration (MIC) of 4.0 mcg/mL or less is considered susceptible for gram-negative bacilli. A MIC of 500 mcg/mL or less is considered synergistic when combined with appropriate antibiotics for treatment of serious enterococcal infections.
Conventional dosing of gentamicin is usually given 2 to 3 times per day by intravenous or intramuscular injections in doses to achieve peak blood concentration between 3.0 to 12.0 mcg/mL depending on the type of infection. Gentamicin also may be administered at higher doses (usually 5-7 mg/kg) once per day to patients with good renal function (known as pulse dosing). Dosing amount or interval must be decreased to accommodate for reduced renal function.
Ototoxicity and nephrotoxicity are the primary toxicities associated with gentamicin. This risk is enhanced in presence of other ototoxic or nephrotoxic drugs. Monitoring of serum levels and symptoms consistent with ototoxicity is important. For longer durations of use, audiology/vestibular testing should be considered at baseline and periodically during therapy.
Reference Values
Therapeutic: <2.0 mcg/mL
Toxic: >2.0 mcg/mL
Interpretation
Goal levels depend on the type of infection being treated. Goal trough levels should be less than 2.0 mcg/mL for conventional dosing. Prolonged exposure to trough levels exceeding 2.0 mcg/mL may lead to toxicity.
Clinical Reference
1. Wilson JW, Estes LL: Mayo Clinic Antimicrobial Therapy Quick Guide, 2008
2. Hammett-Stabler CA, Johns T: Laboratory guidelines for monitoring of antimicrobial drugs. Clin Chem 1998 May;44(5):1129-1140
3. Gonzalez LS III, Spencer JP: Aminoglcosides: a practical review. Am Fam Physician 1998 Nov 15;58(8):1811-1820
Day(s) Performed
Monday through Sunday
Report Available
Same day/1 dayTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
80170
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
GENTA | Gentamicin, Trough, S | 3665-7 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
GENTA | Gentamicin, Trough, S | 3665-7 |
Forms
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
mml-antibiotics, mml-drugmonitoring |